Endocyte Inc. (NASDAQ:ECYT)’s share price was up 3.8% during trading on Tuesday . The company traded as high as $3.05 and last traded at $3.03, with a volume of 68,765 shares trading hands. The stock had previously closed at $2.92.

A number of equities analysts recently commented on ECYT shares. Zacks Investment Research upgraded Endocyte from a “sell” rating to a “hold” rating in a report on Thursday, May 26th. Credit Suisse Group AG restated a “buy” rating on shares of Endocyte in a report on Tuesday, July 12th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $8.69.

The stock has a 50-day moving average price of $3.07 and a 200-day moving average price of $3.40. The stock’s market capitalization is $131.02 million.

Endocyte (NASDAQ:ECYT) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.01. Endocyte had a negative return on equity of 24.71% and a negative net margin of 58,957.14%. During the same period in the prior year, the business posted ($0.25) EPS. Analysts forecast that Endocyte Inc. will post ($1.12) EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its stake in Endocyte by 30,170.2% in the second quarter. JPMorgan Chase & Co. now owns 782,485 shares of the biopharmaceutical company’s stock worth $2,512,000 after buying an additional 779,900 shares during the last quarter. Bellevue Group AG purchased a new stake in Endocyte during the first quarter worth about $310,000. BlackRock Fund Advisors increased its stake in Endocyte by 3.5% in the second quarter. BlackRock Fund Advisors now owns 1,561,432 shares of the biopharmaceutical company’s stock worth $5,012,000 after buying an additional 52,481 shares during the last quarter. Stifel Financial Corp purchased a new stake in Endocyte during the second quarter worth about $127,000. Finally, Bridgeway Capital Management Inc. increased its stake in Endocyte by 11.9% in the second quarter. Bridgeway Capital Management Inc. now owns 195,800 shares of the biopharmaceutical company’s stock worth $629,000 after buying an additional 20,900 shares during the last quarter. 36.48% of the stock is currently owned by institutional investors and hedge funds.

About Endocyte

5 Day Chart for NASDAQ:ECYT

Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.